MedTrace Logo

Methods to Enhance AZR-MD-001 for Meibomian Gland Dysfunction (MGD)

NCT04314362 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2023-01-25

Study results available
· View outcomes & findings →

Summary

Single-center, single-masked (the individual(s) performing efficacy and safety measures will be masked to treatment assignment for the patient(s) they are assessing), vehicle-controlled, randomized study.

Conditions

  • Meibomian Gland Dysfunction

Interventions

DRUG

AZR-MD-001 ointment/semi-solid drug

AZR-MD-001 (1.0%) and suitable excipient

Sponsors & Collaborators

  • The University of New South Wales

    collaborator OTHER

  • Azura Ophthalmics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-14
Primary Completion
2021-01-06
Completion
2021-01-06

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04314362 on ClinicalTrials.gov